Viral Load Analysis of the SARS-CoV-2 Virus in Nose Versus Mouth Sites

Sponsor
IRCCS Sacro Cuore Don Calabria di Negrar (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05769803
Collaborator
(none)
61
1
18.6
3.3

Study Details

Study Description

Brief Summary

It is a single-center, non-profit experimental study, intended to evaluate the viral load of SARS COV 2 in nasal and oral samples of positive subjects to evaluate any variation and understand which is the most suitable site for carrying out the swab.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Nasal and mouth swab
N/A

Detailed Description

Experimental study on de-identified, biological samples (nasal and buccal swab).

The study will be performed on patients admitted to IRCCS Sacro Cuore Don Calabria Hospital or health care workers or their family members, who tested positive for SARS-CoV-2 by either a molecular or antigen test, performed on nasopharyngeal swab, according to current diagnostics.

Among the family members, also children >4 years old will be included. The reason for including children and young subjects is based on data indicating that they seems to be highly sensitive to Omicron infection and that their vaccination status could influence viral load. The nose and mouth swab are poor invasive and they could be well tolerated also by children.

Whinin 7 days from diagnosis, the subjects will be requested to sample another two specimens i.e. nasal swab and mouth swab, that will be tested for the presence of SARS-CoV-2 RNA. Results, expressed as cycle threshold will be then compared to analyze viral loads from the two different sites.

Moreover, an aliquot will be retro-transcribed into cDNA and sequenced by Next Generation Sequencing (NGS) to obtain the virus entire genome sequence or evaluated by RT-PCR for variant determination.

Study Design

Study Type:
Interventional
Actual Enrollment :
61 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Viral Load Analysis of the SARS-CoV-2 Virus in Nose Versus Mouth Sites
Actual Study Start Date :
Mar 14, 2022
Actual Primary Completion Date :
Feb 14, 2023
Anticipated Study Completion Date :
Sep 30, 2023

Outcome Measures

Primary Outcome Measures

  1. SARS-CoV-2 real time RT-PCR analysis results of the nose and mouth swabs. [2 months]

    SARS-CoV-2 real time RT-PCR analysis results of the nose and mouth swabs.

  2. - Droplet digital PCR (ddPCR) results for SARS-CoV-2 [2 months]

    - Droplet digital PCR (ddPCR) results for SARS-CoV-2

  3. - NGS or RT-PCR results for genomic lineages or variant identification. [2 months]

    - NGS or RT-PCR results for genomic lineages or variant identification.

  4. - RT-PCR analysis results for subgenomics [2 months]

    - RT-PCR analysis results for subgenomics

Secondary Outcome Measures

  1. SARS-CoV-2 real time RT-PCR analysis results of the nose and mouth swabs in relationship to the sampling site, to the viral characterization and to the time from diagnosis. [2 months]

    SARS-CoV-2 real time RT-PCR analysis results of the nose and mouth swabs in relationship to the sampling site, to the viral characterization and to the time from diagnosis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients admitted to IRCCS Sacro Cuore Don Calabria Hospital or health care workers or their family members. Among the family members, also children >4 years old will be included.

  • Subjects verified as positive to SARS-CoV-2 according to either a molecular or antigen test, performed on nasopharyngeal swab, according to current diagnostics.

  • Subjects who will accept to participate to the study and will sign the informed consent.

Exclusion Criteria:
  • lack of any needed data or inform consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Sacro Cuore Don Calabria hospital Negrar Verona Italy 37024

Sponsors and Collaborators

  • IRCCS Sacro Cuore Don Calabria di Negrar

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
IRCCS Sacro Cuore Don Calabria di Negrar
ClinicalTrials.gov Identifier:
NCT05769803
Other Study ID Numbers:
  • 2022-04
First Posted:
Mar 15, 2023
Last Update Posted:
Mar 15, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2023